Join Growin Stock Community!

Akari therapeutics, plcAKTX.US Overview

US StockHealthcare
(No presentation for AKTX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

AKTX AI Insights

AKTX Overall Performance

AKTX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

AKTX Recent Performance

1.61%

Akari therapeutics, plc

0.05%

Avg of Sector

-0.31%

S&P500

AKTX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

AKTX Key Information

AKTX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

AKTX Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Price of AKTX

AKTX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

AKTX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-882.60
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.48
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
0.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-882.60
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.48
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
0.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is AKTX's latest earnings report released?

    The most recent financial report for Akari therapeutics, plc (AKTX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating AKTX's short-term business performance and financial health. For the latest updates on AKTX's earnings releases, visit this page regularly.

  • How much cash does AKTX have?

    At the end of the period, Akari therapeutics, plc (AKTX) held Total Cash and Cash Equivalents of 2.54M, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • What is the FCF of AKTX?

    Akari therapeutics, plc (AKTX)'s Free Cash Flow (FCF) for the period is -2.12M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 42.35% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of AKTX?

    The latest valuation data shows Akari therapeutics, plc (AKTX) has a Price-To-Earnings (PE) ratio of -1.18 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.